Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clopidogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.98 |
| ▸ | THRB | P10828 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.62 |
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clopidogrel SCHEMBL1031047 | 1.00 | ABCB11 (0.98) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL27927313 | 0.99 | ABCB11 (0.96) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL29793709 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL5567933 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031641 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL754557 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL30388817 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031319 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL14009483 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL4769 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606231-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | Nadkarni, Sunil Sadanand (IN) | 2005-12-21 | — | — | EP | claimed |
| WO-2004074215-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | NADKARNI SUNIL SADANAND (IN) | 2004-09-02 | — | — | WO | claimed |
| CN-112955124-A | Oral film compositions and dosage forms having precise active dissolution profiles | 阿奎蒂夫疗法公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-102186858-A | Process for the preparation of S-clopidogrel | SANDOZ AG | 2011-09-14 | — | — | CN | disclosed |
| US-7652139-B2 | Clopidogrel salt and polymorphic forms thereof | SANOFI-AVENTIS (FR) | 2010-01-26 | — | — | US | disclosed |
| CN-100503615-C | Method of preparing chloropy gra hydrogen sulphate type I | SHANGHAI KAITE INTERNAT TRADE (CN) | 2009-06-24 | — | — | CN | disclosed |
| US-20070088049-A1 | POLYMORPHIC FORMS OF METHYL (+)-(S) - ALPHA - (2-CHLOROPHENYL)-6, 7-DIHYDROTHIENO [3,2-C]PYRIDINE-5(4H) ACETATE HYDROBROMIDE, CLOPIDOGREL HYDROBROMIDE | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | US | disclosed |
| US-20070088048-A1 | CLOPIDOGREL SALT AND POLYMORPHIC FORMS THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | US | disclosed |
| EP-1756116-A1 | POLYMORPHIC FORMS OF METHYL(+)-(S)-ALPHA-(2-CHLOROPHENYL)-6,7-DIHYDROTHIENO[3,2-C]PYRIDINE-5(4H) ACETATE HYDROBROMIDE, CLOPIDROGEL HYDROBROMIDE | Sanofi-Aventis (FR) | 2007-02-28 | — | — | EP | disclosed |
| CN-1903859-A | Method of preparing chloropy gra hydrogen sulphate type I | SHANGHAI COLLEGE OF APPLIED TE (CN) | 2007-01-31 | — | — | CN | disclosed |
| EP-1740594-A1 | CLOPIDOGREL SALT AND POLYMORPHIC FORMS THEREOF | Sanofi-Aventis (FR) | 2007-01-10 | — | — | EP | disclosed |
| EP-1606231-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | Nadkarni, Sunil Sadanand (IN) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005103059-A1 | CLOPIDOGREL SALT AND POLYMORPHIC FORMS THEREOF | SANOFI-AVENTIS (FR) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005103058-A1 | POLYMORPHIC FORMS OF METHYL (+) - (S) -ALPHA- (2-CHLOROPHENYL) -6, 7-DIHYDROTHIENO `3,2-C!PYRIDINE-584H) ACETATE HYDROBROMIDE, CLOPIDROGEL HYDROBROMIDE | SANOFI-AVENTIS (FR) | 2005-11-03 | — | — | WO | disclosed |
| EP-1474427-A1 | POLYMORPHS OF CLOPIDOGREL HYDROCHLORIDE AND THEIR USE AS ANTITHROMBIC COMPOUNDS | EGIS GYOGYSZERGYAR (HU) | 2004-11-10 | — | — | EP | disclosed |
| WO-2004074215-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS | NADKARNI SUNIL SADANAND (IN) | 2004-09-02 | — | — | WO | disclosed |
| WO-2003066637-A1 | POLYMORPHS OF CLOPIDOGREL HYDROCHLORIDE AND THEIR USE AS ANTITHROMBIC COMPOUNDS | EGIS Gyógyszergyár Rt. (HU) | 2003-08-14 | — | — | WO | disclosed |
| US-6504030-B1 | Methyl (+)-(S)- alpha -(2-chlorophenyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridine-5-acetate camphorsulfonate is suspended in an organic solvent, camphorsulfonic acid is extracted with potassium carbonate, salt forming with H2SO4 | SANOFI-SYNTHELABO (FR) | 2003-01-07 | — | — | US | disclosed |
| US-20020198229-A1 | POLYMORPHIC FORM OF CLOPIDOGREL HYDROGEN SULPHATE | SANOFI-AVENTIS (FR) | 2002-12-26 | — | — | US | disclosed |
| US-6429210-B1 | ORTHOROMBIC POLYMORPH OF CLOPIDOGREL HYDROGEN SULFATE WITH IMPROVED STABILITY AND LOWER SOLUBILITY; ANTITHROMBOTIC AGENT; SPECIFIC CRYSTAL STRUCTURE AND THERMODYNAMIC PROPERTIES | SANOFI-SYNTHELABO (FR) | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088048-A1 | CLOPIDOGREL SALT AND POLYMORPHIC FORMS THEREOF | P2RY13, P2RY12, P2RY11 | P2RY12 2/4885ABCB11 32/4885OPRM1 3463/4885 |
| US-20070088049-A1 | POLYMORPHIC FORMS OF METHYL (+)-(S) - ALPHA - (2-CHLOROPHENYL)-6, 7-DIHYDROTHIENO [3,2-C]PYRIDINE-5(4H) ACETATE HYDROBROMIDE, CLOPIDOGREL HYDROBROMIDE | P2RY11, P2RY4, P2RY13 | P2RY12 4/4885ABCB11 348/4885OPRM1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.